Int J Clin Rheumatol. 2010;5(4):407-413.

Impact and progress Frontiers' impact Progress Report 2022 All progress reports ...

Benlysta binds and neutralises the B cell survival factor BAFF, while rituximab targets CD20, a protein found on the surface of B cells. The anti-CD20 mechanism could also lead to some competition ...

Structure-based drug design is the design and optimization of a chemical structure with the goal of identifying a compound suitable for clinical testing — a drug candidate. It is based on ...

It includes the study of rates of sequence change, relative importance of adaptive and neutral changes, and changes in genome structure. Origins-of-life research has focused on specific chemical ...

Researchers have profiled the molecular structure and features of a key part of the deadly Nipah virus. Experiments in cells showe how changes in the viral polymerase -- a protein involved in ...

Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, Katahira, Aoba-ku, Sendai 980-8577, Japan ...

Finally, we show that there is substantial overlap between the molecular networks that define these disease states across species. Our synthesis and analysis of the current state of the field are ...

It is notoriously hard to treat effectively. Saphnelo will compete in the market most closely with GlaxoSmithKline's BLyS inhibitor Benlysta (belimumab), which has been available in the EU to ...